Jazz Pharmaceuticals (JAZZ) Other Non-Current Liabilities (2012 - 2026)

Jazz Pharmaceuticals' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $161.5 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 77.24% year-over-year to $161.5 million in Q1 2026; TTM through Mar 2026 was $161.5 million, a 77.24% increase from a year earlier, with the FY2025 full-year figure at $124.4 million, up 43.63% from the prior year.
• Other Non-Current Liabilities advanced to $161.5 million in Q1 2026 per JAZZ's latest filing, from $124.4 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $161.5 million in Q1 2026 and bottomed at $86.6 million in Q4 2024.
• The 5-year median for Other Non-Current Liabilities is $122.7 million (2023), against an average of $116.6 million.
• Across the five-year window, Other Non-Current Liabilities declined 29.41% in 2024 and surged 77.24% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $144.0 million in 2022, then declined by 14.78% to $122.7 million in 2023, then decreased by 29.41% to $86.6 million in 2024, then soared by 43.63% to $124.4 million in 2025, then increased by 29.82% to $161.5 million in 2026.
• Per Business Quant, the three latest JAZZ Other Non-Current Liabilities figures stand at $161.5 million (Q1 2026), $124.4 million (Q4 2025), and $108.9 million (Q3 2025).